13C tracing in synaptosomes reveals that SGLT2 inhibition with dapagliflozin prevents metabolic deficits in the 5X-FAD model of Alzheimer’s Disease. Here, SLC5A2 is linked to early-onset autosomal dominant Alzheimer disease.